JW PHARMACEUTICAL
KOSPI
₩26,600.00
-0.56%
Delayed · cached 15 min
Fair value analysis
001060
JW PHARMACEUTICAL
₩26,600.00
Close used for this calculation
₩45,650.65Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
62/100
Quality radar
Consensus fair value
₩45,650.65
Below FV▲ +71.6% against the close used
Model range ₩7,122.15 – ₩65,339.67
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩7,122.15Fair value₩45,650.65Bull₩65,339.67
FairClose
52-week traded range
52W low ₩20,950.0052W high ₩39,050.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
JW PHARMACEUTICAL closed at ₩26,600.00, 41.7% below the consensus fair value of ₩45,650.65 drawn from 8 valuation models.
Financial DNA score 62/100 — Good. P/E of 10.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩65,339.67
+145.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩30,596.93
+15.0%
√(22.5 × EPS × BVPS)
EPS=2534, BVPS=16419.75
P/E Fair Value
₩50,680.00
+90.5%
EPS × 20x (sector P/E)
EPS=2534, Sector P/E=20x
EV/EBITDA
₩37,591.45
+41.3%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=94.46B
Dividend Discount (DDM)
₩7,122.15
-73.2%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=558.6, r=10%, g=2%
Book Value (P/B)
₩32,018.52
+20.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=16419.75, ROE=16.7%, g=3%, r=10%
Reverse DCF
₩26,600.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -1.6% | Historical: 0%
Margin of Safety
₩36,654.15
+37.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=48872.2, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.